ScreenerHero
LNTHLantheus Holdings Inc
NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · lantheus.com
100.33USD-0.14%Mkt Cap: 6.56B $P/E: 24.04

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers …

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$65.19BUSDP/E 23.7
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.41BUSDP/E 20.1
ZOE
Zoetis Inc.
$29.89BUSDP/E 12.7
UTHR
United Therapeutics Corporation
$22.70BUSDP/E 19.0
VTRS
Viatris, Inc.
$18.66BUSD
SOBI
Swedish Orphan Biovitrum AB (publ)
$15.34BUSDP/E 117.3
NBIX
Neurocrine Biosciences, Inc.
$15.81BUSDP/E 22.8
IPN
Ipsen S.A.
$14.67BUSDP/E 26.4
ELAN
Elanco Animal Health Incorporat
$12.24BUSD
KRK
Krka, d. d.
$8.66BUSDP/E 19.0
HIMS
Hims & Hers Health, Inc.
$7.25BUSD
LQDA
Liquidia Corporation
$6.74BUSDP/E 53.8
AMRX
Amneal Pharmaceuticals, Inc.
$6.23BUSDP/E 37.3
INDV
Indivior PLC Ordinary Shares
$4.61BUSDP/E 14.0
SFZN
Siegfried Holding AG
$4.01BUSDP/E 20.9
AMLX
Amylyx Pharmaceuticals Inc. Common Stock
$4.30BUSD
HIK
Hikma Pharmaceuticals PLC
$3.69BUSDP/E 12.7
ROVI
Laboratorios Farmaceuticos Rovi, S.A.
$3.32BUSDP/E 16.5
SUPN
Supernus Pharmaceuticals, Inc.
$2.82BUSD
ALM
Almirall, S.A.
$2.47BUSDP/E 37.4

Key Statistics

Company
Market Cap6.56B $
Enterprise Value6.57B $
Revenue (TTM)1.56B $
Gross Profit941.95M $
Net Income (TTM)233.56M $
Revenue/Share23.70 USD
Last Price100.33 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees1.2K
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINUS5165441032
Valuation
P/E (Trailing)24.04
P/E (Forward)15.85
PEG—
EV/EBITDA16.76
EV/Revenue4.22
P/S4.20
P/B4.99
EPS (TTM)4.17
EPS (Forward)6.32
52W Range
49.6781% of range111.86
52W High111.86 USD
52W Low49.67 USD
Profitability
Gross Margin61.10%
Oper. Margin25.82%
EBITDA Margin25.20%
Profit Margin15.15%
ROE21.43%
ROA10.49%
Growth
Revenue Growth2.70%
Earnings Growth-0.90%
Cash Flow & Leverage
Operating CF390.14M $
CapEx (TTM)41.50M $
FCF Margin29.02%
FCF Yield6.89%
Net Debt31.66M $
Net Debt/EBITDA0.08
Balance Sheet
Debt/Equity0.57
Current Ratio3.06
Quick Ratio2.82
Book Value/Sh20.10 USD
Cash/Share9.090 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.5 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)107.04 USD
Upside (mean)+6.7%
Target Range102.50 USD – 115.00 USD
$102.50+6.7% to mean$115.00
# Analysts10
Ownership
Shares Out.65.27M
Float58.53M
Insiders2.08%
Institutions117.16%
Short Interest
Short Ratio7.0d
Short % Float12.85%
Short % Out.9.67%
Shares Short6.31M
Short (prev mo.)6.33M
Technical
SMA 50103.99 (-3.5%)
SMA 20081.64 (+22.9%)
Beta-0.03
S&P 52W Chg18.16%
Avg Vol (30d)1.49M
Avg Vol (10d)1.83M
Technical Indicators
RSI (14)44.0
MACD-0.8650
MACD Signal-0.7927
MACD Hist.-0.0723
BB Upper105.85 USD
BB Middle101.80 USD
BB Lower97.74 USD
BB Width7.96%
ATR (14)1.939 USD
Vol Ratio (20d)0.58x